#+TITLE: CMU Chemical Engineering
Description: Papers by people in the Department of Chemical Engineering at CMU
Created on Sat Mar  8 01:07:47 2025

Found 1 results from 2025-03-01 to 2025-03-08
OpenAlex URLS (not including from_created_date or the API key)
- [[https://api.openalex.org/works?filter=author.id%3Ahttps%3A//openalex.org/A5063320716%7Chttps%3A//openalex.org/A5052825722%7Chttps%3A//openalex.org/A5010387303%7Chttps%3A//openalex.org/A5041685684%7Chttps%3A//openalex.org/A5040842816%7Chttps%3A//openalex.org/A5048633127%7Chttps%3A//openalex.org/A5048485981%7Chttps%3A//openalex.org/A5086004922%7Chttps%3A//openalex.org/A5056017028%7Chttps%3A//openalex.org/A5018420940%7Chttps%3A//openalex.org/A5003442464%7Chttps%3A//openalex.org/A5055700187%7Chttps%3A//openalex.org/A5030631754%7Chttps%3A//openalex.org/A5044695139%7Chttps%3A//openalex.org/A5028498558%7Chttps%3A//openalex.org/A5053252662%7Chttps%3A//openalex.org/A5028147543%7Chttps%3A//openalex.org/A5037506064%7Chttps%3A//openalex.org/A5027983186%7Chttps%3A//openalex.org/A5010666650]]

* Enhanced epigenetic modulation via mRNA-encapsulated lipid nanoparticles enables targeted anti-inflammatory control  :CMU_Chemical_Engineering:
:PROPERTIES:
:UUID: https://openalex.org/W4408057088
:TOPICS: RNA Interference and Gene Delivery, Adenosine and Purinergic Signaling, Extracellular vesicles in disease
:PUBLICATION_DATE: 2025-02-28
:END:    
    
[[elisp:(doi-add-bibtex-entry "https://doi.org/10.1101/2025.02.24.639996")][Get bibtex entry]] 

- [[elisp:(progn (xref--push-markers (current-buffer) (point)) (oa--referenced-works "https://openalex.org/W4408057088"))][Get references]]
- [[elisp:(progn (xref--push-markers (current-buffer) (point)) (oa--related-works "https://openalex.org/W4408057088"))][Get related work]]
- [[elisp:(progn (xref--push-markers (current-buffer) (point)) (oa--cited-by-works "https://openalex.org/W4408057088"))][Get cited by]]

OpenAlex: https://openalex.org/W4408057088 (Open access: True)
    
[[https://openalex.org/A5043231266][Tahere Mokhtari]], [[https://openalex.org/A5036114929][Mohammad Taheri]], [[https://openalex.org/A5030263255][Sarah Akhlaghi]], [[https://openalex.org/A5027837077][Armin Aryannejad]], [[https://openalex.org/A5102928777][Yang Xiang]], [[https://openalex.org/A5019570543][Vineet Mahajan]], [[https://openalex.org/A5004559321][Kamyar Keshavarz F.]], [[https://openalex.org/A5112390703][Amirreza Kiani]], [[https://openalex.org/A5064315710][Samuel T. LoPresti]], [[https://openalex.org/A5009054892][Ryan LeGraw]], [[https://openalex.org/A5010666650][Kathryn A. Whitehead]], [[https://openalex.org/A5028774736][Samira Kiani]], bioRxiv (Cold Spring Harbor Laboratory). None(None)] 2025. https://doi.org/10.1101/2025.02.24.639996 
     
Temporal transcriptional modulation of immune-related genes offers powerful therapeutic potential for treating inflammatory diseases. Here, we introduce an enhanced zinc finger (ZF)-based transcriptional repressor delivered via lipid nanoparticles for controlling immune signaling pathways in vivo. By targeting Myd88, an essential adaptor molecule involved in immunity, our system demonstrates therapeutic efficacy against septicemia in C57BL/6J mice and improves repeated AAV administration by reducing antibody responses. This epigenetic engineering approach provides a platform for safe and efficient immunomodulation applicable across diseases caused by imbalanced inflammatory responses.    

    
